119 results
8-K
EX-99.1
TGTX
TG Therapeutics, Inc.
14 Jan 25
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones
4:02pm
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
1. MS Prevalence. National Multiple Sclerosis Society website … . https://www.nationalmssociety.org/About-the-Society/MS-Prevalence. Accessed October 26, 2020. 2. Multiple Sclerosis International Federation, 2013 via Datamonitor p. 236.
8-K
EX-99.1
TGTX
TG Therapeutics, Inc.
4 Nov 24
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
7:19am
: 1.877.575.TGTX (8489), Option 6 1. MS Prevalence. National Multiple Sclerosis Society website. https://www.nationalmssociety.org/About-the-Society/MS
8-K
EX-99.1
TGTX
TG Therapeutics, Inc.
6 Aug 24
TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
7:08am
. National Multiple Sclerosis Society website. https://www.nationalmssociety.org/About-the-Society/MS-Prevalence. Accessed October 26, 2020. 2. Multiple
8-K
EX-99.1
8rjhlcrenapovo8olvss
1 May 24
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
7:05am
8-K
EX-99.1
26b8mw 7w
28 Feb 24
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
7:24am
8-K
EX-99.1
vbrzc
10 Jan 24
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
7:37am
8-K
EX-99.1
a8hqjzl2 1xu
1 Nov 23
TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
7:33am
8-K
EX-99.1
9qoxg 3f6ncu
1 Aug 23
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
7:29am
8-K
EX-99.1
bnanot
1 May 23
TG Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
7:35am
8-K
EX-99.1
w2sqps3d6b tun18cfa
28 Dec 22
U.S. Commercial launch expected Q1 2023
4:30pm